267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819181176639717376 |
|---|---|
| author | Shahram Salek-Ardakani Wenjing Yang Sheng Ding Shih-Hsun Chen Jessica Stanfield Nadia Kurd Ryan Llewellyn Jonathan Heyen Carole Wang Zea Melton Javier Chaparro-Riggers Pawel Dominik Kevin Lindquist Thomas Van Blarcom |
| author_facet | Shahram Salek-Ardakani Wenjing Yang Sheng Ding Shih-Hsun Chen Jessica Stanfield Nadia Kurd Ryan Llewellyn Jonathan Heyen Carole Wang Zea Melton Javier Chaparro-Riggers Pawel Dominik Kevin Lindquist Thomas Van Blarcom |
| author_sort | Shahram Salek-Ardakani |
| collection | DOAJ |
| first_indexed | 2024-12-22T22:26:05Z |
| format | Article |
| id | doaj.art-1f019c3519b849a08123380e84c26521 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-22T22:26:05Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-1f019c3519b849a08123380e84c265212022-12-21T18:10:33ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.267267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic windowShahram Salek-Ardakani0Wenjing Yang1Sheng Ding2Shih-Hsun Chen3Jessica Stanfield4Nadia Kurd5Ryan Llewellyn6Jonathan Heyen7Carole Wang8Zea Melton9Javier Chaparro-Riggers10Pawel Dominik11Kevin Lindquist12Thomas Van Blarcom13Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USAComputational Biology, Pfizer Inc, San Diego, California, USABioMedicine Design, Pfizer Inc, San Diego, California, USACancer Immunology Discovery, Pfizer Inc, San Diego, California, USACancer Immunology Discovery, Pfizer Inc, San Diego, California, USACancer Immunology Discovery, Pfizer Inc, San Diego, California, USACancer Immunology Discovery, Pfizer Inc, San Diego, California, USADrug Safety R&D, Pfizer Inc, San Diego, California, USABioMedicine Design, Pfizer Inc, San Diego, California, USABioMedicine Design, Pfizer Inc, San Diego, California, USABioMedicine Design, Pfizer Inc, San Diego, California, USAPfizer, San Diego, CA, USAPfizer, San Diego, CA, USAPfizer, San Diego, CA, USA |
| spellingShingle | Shahram Salek-Ardakani Wenjing Yang Sheng Ding Shih-Hsun Chen Jessica Stanfield Nadia Kurd Ryan Llewellyn Jonathan Heyen Carole Wang Zea Melton Javier Chaparro-Riggers Pawel Dominik Kevin Lindquist Thomas Van Blarcom 267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window Journal for ImmunoTherapy of Cancer |
| title | 267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window |
| title_full | 267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window |
| title_fullStr | 267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window |
| title_full_unstemmed | 267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window |
| title_short | 267 Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window |
| title_sort | 267 dual checkpoint blockade of cd47 and pd l1 using an affinity tuned bispecific antibody maximizes anti tumor immunity and improves therapeutic window |
| work_keys_str_mv | AT shahramsalekardakani 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT wenjingyang 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT shengding 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT shihhsunchen 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT jessicastanfield 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT nadiakurd 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT ryanllewellyn 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT jonathanheyen 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT carolewang 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT zeamelton 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT javierchaparroriggers 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT paweldominik 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT kevinlindquist 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow AT thomasvanblarcom 267dualcheckpointblockadeofcd47andpdl1usinganaffinitytunedbispecificantibodymaximizesantitumorimmunityandimprovestherapeuticwindow |